The mouse models fall into two categories:1) transgenics bred onto Smn null or Δ7 backgrounds to rescue the embryonic lethality of homozygous Smn mutants to produce varying degrees of SMA severity, and 2) modifications of the endogenous Smn locus that reduce Smn expression. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.